Governance

Governance

Board of directors

The Board of Directors has international competence and extensive industry experience in life science.

Lennart Hansson

Chairman, Co-Founder. Born 1956. Board member since 2014.

Nationality: Swedish

Education: Ph.D. in Genetics from Umeå University.

Board Committees: Member of the Remuneration Committee.

Experience: Former head of Life Science Investments at Industrifonden. Previously Hansson has more than 25 years’ experience from pharma and biotech industry in executive position at KabiGen, Symbicom AB, AstraZeneca AB, Karolinska Development AB and BioVitrum AB and as CEO for Arexis AB. He has a PhD from Umeå University. Co-founder of Cinclus Pharma.

Other assignments: Member of the Board of InDex Pharmaceuticals AB and Medivir aktiebolag. Chairman of the Board of Ignitus AB and Sixera Pharma AB.

Independent/Dependent of the company major owners: Independent in relation to the Company and its management and in relation to major shareholders.

cinclus pharma board member Wenche Rolfsen

Wenche Rolfsén

Non-executive Director. Born 1952. Board member since 2016.

Nationality: Swedish

Education: Pharmacist, Doctor of Pharmacy (pharma-cognosy), Adjunct Professor at Uppsala University, Sweden

Board Committees: Member of the Audit committee.

Experience: Former Head of pharmacology at Pharmacia & Upjohn; VP clinical trials Quintiles Europe, CEO of Quintiles Scandinavia. Chairman of Aprea Therapeutics AB, Denator AB and Aprea Personal AB. Board member of SOBI AB, Recipharm AB, Smartfish AB, Moberg Pharma AB, TFS Trial Form Support Internatio-nal AB, Apotek Produktion & Laboratorier AB and Industrifonden.

Other assignments: Chairman of the Board of Bioartic AB and Index Pharmaceutical Holding AB. Member of the Board of Index Diagnostics AB and CEO and Boardmember in Rolfsén Consulting AB. Partner in Serendipity Partners.

Independent/Dependent of the company major owners: Independent in relation to the Company and its management and in relation to major shareholders.

Peter Unge

Non-executive Director, Senior Adviser, Co-founder. Born 1951. Board member since 2014.

Nationality: Swedish

Education: MD. Ph.D. Gastroenterologist and Internal Medicine and Hepatology from Karolinska Institutet, Stockholm, Sweden.

Experience: 27 years of Clinical experience. Consultant at AstraZeneca and former VP at Novartis. Developed the first modern H. pylori eradication therapy principles.

Other assignments: Member of the Board of PetoMaj Invest AB.

Independent/Dependent of the company major owners: Not independent in relation to the Company and its management but independent in relation to major shareholders.

Torbjörn Koivisto

Non-executive Director. Born 1969. Board member since 2017.

Nationality: Swedish

Education: Master of Laws (LL.M.), University of Uppsala, Sweden.

Board Committees: Chairman of the Remuneration committee.

Experience: More than 20 years’ experience as a business lawyer, focusing entirely on advising clients within the life sciences industry on matters of commercial and corporate law. Previous work experience includes law firms Mannheimer Swartling, Lindahl and Bird & Bird. Since 2006 working for his own company IARU.

Other assignments: Member of the Board of Xspray Pharman and IARU Institutet för Affärsjuridisk Rådgivning i Uppsala AB.

Independent/Dependent of the company major owners: Independent in relation to the Company and its management and in relation to major shareholders.

Anders Öhberg

Non-executive Director. Born 1980. Board member since 2016.

Nationality: Swedish

Education: Master of Medical Sciences and Clinical Drug Development from Uppsala University.

Experience: More than 15 years experience from drug development and medical affairs within the pharmaceutical industry. He has held a broad spectrum of positions within clinical development, pharmacovigilance, quality assurance and medical affairs at Pfizer, Ipsen, Shire and Novartis. Currently heading the medical affairs department in the Nordics and top 5 European countries for gene therapy at Novartis within ophthalmology.

Other assignments: Member of the Board in Regulus Pharma Fas1 AB.

Independent/Dependent of the company major owners: Independent in relation to the Company and its management and in relation to major shareholders.

Helena Levander

Non-executive Director. Born 1957. Board member since 2021.

Nationality: Swedish

Education: Master in Finance and Business Administration from Stockholm School of Economics.

Board Committees: Chairman of the Audit committee.

Experience: More than 20 years of experience within asset management and equity markets from SEB, Nordea, Odin Funds and Neonet Securities.

Other assignments: Chairman of the Board in Factoringgruppen AB and Caroline Svedbom AB. Board member of Rejlers AB (publ), Stendörren Fastigheter AB and Occlutech AG.

Independent/Dependent of the company major owners: Independent in relation to the Company and its management and in relation to major shareholders.

Nina Rawal

Non-executive Director. Born 1979. Board member since 2022.

Nationality: Swedish

Education: PhD in Molecular Neurobiology from Karolinska Institutet.

Board Committees: Chairman of the Audit committee.

Experience: Currently Partner and Co-Head at Trill Impact Ventures. Previous experience includes the roles of Head of life science at Industrifonden, Vice President, Strategy and Ventures at Gambro, and management consulting at Boston Consulting Group in Stockholm and New York.

Other assignments: Board member in Emerging Health Ventures I AB and serves on the board of Stockholms Sjukhem.

Independent/Dependent of the company major owners: Independent in relation to the Company and its management and in relation to major shareholders.